Efficacy and safety of everolimus for patients with focal cortical dysplasia type 2.

Epilepsia Open · 2025 · PMC11803298 · PMID 39607729

Europe PMC DOI

hedged sentence

0.3300

closest p · 6.6× alpha

0.3300

boldest claim

The sentences

did not reach statistical significancep = 0.33not close (p > 0.1)

This trend tended to be sustained throughout the core phase, but it did not reach statistical significance at Week 8 (estimated difference, 0.04; 95% CI, −0.04–0.12; p = 0.33) or Week 12 (estimated difference, 0.04; 95% CI, −0.05 to 0.13, p = 0.32).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.